Molecular Research and New Therapy in Melanoma and Other Skin Cancers 2.0

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, titled “Molecular Research and New Therapy in Melanoma and Other Skin Cancers”.

Although we are experiencing increasing success in skin cancer therapy (especially malignant melanoma) by using immune checkpoint inhibition (ICI-) mono as well as combined therapy, skin cancer is still the most frequent cancer in the white population, causing more than 60,000 melanoma-related deaths worldwide each year. The reasons for this are primary and secondary (acquired) resistance against modern ICI therapies, as well as missing information about basic molecular events that induce skin cancer and therapy resistance. Therefore, there is an urgent need to increase evidence-based knowledge in molecular oncology, personalized diagnostics, precision medicine, and predictive assays to find early diagnostic, progression, and predictive molecular biomarkers to monitor skin cancer. Topics that should be focused on in the future (in addition to others) include tumor heterogeneity, tumor-microenvironment interaction (e.g., via exosomes), skin cancer biomarkers, transcriptomics, proteomics, epigenomics, immunomodulation, and the use of high throughput technologies. The main feature of this Special Issue is to provide a recent overview of ongoing molecular research by top experts in skin cancer development and therapy.

Dr. Rüdiger Greinert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• epigenetics
• cancer stem cells
• noncoding RNA (miRNA)
• personalized diagnostic (medicine)
• personalized medicine
• DNA repair
• skin cancer biomarker
• skin cancer prevention
• genomics
• transcriptomics
• immunomodulation
• ctDNA
• circulating tumor cells
• liquid biopsy